COVID-19 in Lymphangioleiomyomatosis: An International Study of Outcomes and Impact of Mechanistic Target of Rapamycin Inhibition

Affiliations

• ¹ Divisão de Pneumologia, Instituto do Coração (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil. Electronic address: bruno.baldi@hc.fm.usp.br.
• ² National Tuberculosis and Lung Diseases Research Institute, Warsaw, Poland.
• ³ National Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, Hospices Civils de Lyon, University of Lyon, INRAE, Lyon, France.
• ⁴ Division of Pulmonary and Critical Care, Loyola University Chicago, Stritch School of Medicine, Maywood, IL.
• ⁵ Division of Pulmonary, Critical Care and Sleep Medicine, University of Florida, Gainesville, FL.
• ⁶ Divisão de Pneumologia, Instituto do Coração (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.
• ⁷ Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy; Department of Medicine, Ospedale San Giuseppe MultiMedica IRCCS, Milan, Italy.
• ⁸ ILD Program, Department of Medicine, National Jewish Health, Denver, CO.
• ⁹ ILD Center of Excellence, St. Antonius Hospital Nieuwegein, University Medical Center Utrecht, Utrecht, The Netherlands.
• ¹⁰ Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka, Japan.
• ¹¹ Division of Pulmonary, Critical Care and Sleep Medicine, University of Cincinnati, Cincinnati, OH.
• ¹² Translational Medical Sciences, NIHR Biomedical Research Centre and Biodiscovery Institute, University of Nottingham, Nottingham, England; National Centre for Lymphangioleiomyomatosis, Nottingham University Hospitals NHS Trust, Nottingham, England.